Related Experiment Video

Updated: Jul 5, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress?

Brian I Rini1, Ronald M Bukowski

  • 1Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological and Kidney Institute, Cleveland, Ohio 44195, USA. rinib2@ccf.org

Oncology (Williston Park, N.Y.)
|May 14, 2008
PubMed

Insights

Targeted therapies, including sunitinib and bevacizumab, show significant clinical effects in metastatic renal cell carcinoma (RCC). Optimal timing and sequencing of these vascular endothelial growth factor (VEGF) pathway agents remain key clinical questions for future research.

Area of Science:

  • Oncology
  • Translational Medicine
  • Pharmacology

Background:

  • Recent biological insights into renal cell carcinoma (RCC) have informed new therapeutic strategies.
  • Metastatic RCC treatment has historically relied on less effective options.
  • The vascular endothelial growth factor (VEGF) pathway is a key target in RCC biology.

Purpose of the Study:

  • To review the current landscape of targeted therapies for metastatic RCC.
  • To discuss the clinical efficacy and established roles of novel agents.
  • To identify emerging clinical questions regarding treatment sequencing and novel agent development.

Main Methods:

  • Review of recent clinical trial data and established treatment guidelines.
  • Analysis of targeted therapies focusing on the VEGF pathway and related targets.
  • Discussion of agents like sunitinib, bevacizumab, sorafenib, and temsirolimus.

Main Results:

  • Targeted therapies, particularly anti-VEGF agents, demonstrate superior clinical effects compared to historical treatments.
  • Sunitinib and bevacizumab plus interferon are established first-line options for metastatic RCC.
  • Sorafenib is indicated for cytokine-refractory RCC, and temsirolimus has shown overall survival benefits in poor-risk populations.

Conclusions:

  • Targeted therapies have revolutionized metastatic RCC treatment, offering improved outcomes.
  • Optimal sequencing and timing of these therapies require further clinical investigation.
  • Ongoing research into novel agents targeting VEGF and alternative pathways holds promise for future treatment advancements.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...